Skip to main content
Caplight Logo









Virano Therapeutics

Virano Therapeutics

Private
TorontoHealthcare & Life Scienceshttps://viranotx.com/

Last Round

Grant

Oct 23, 2025

Company Overview

Virano Therapeutics is a biotechnology company that develops genetic immunomodulation products and combination therapies to treat solid tumors and genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

genetic immunomodulationgene delivery systemsvector potentiatorsVEPOscombination therapygene therapybiotech R&Dsolid tumor treatmentgenetic disease therapydrug discoverybiotech licensingnext-gen gene therapypreclinical biotechtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Virano Therapeutics Comparables

Compare Virano Therapeutics with similar companies based on industry and business-model similarity.

Virano Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SIRION Biotech
73%
Mediphage Bioceuticals
72%
Virica Biotech
66%

Virano Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 23, 2025
AcceleratorDec 3, 2024
SeedNov 20, 2023

Key People

Founding team and executive leadership

Ella Korets-Smith

CEO And Co-Founder

Founding Team

Virano Therapeutics Investors

Notable investors and investment history

Virano Therapeutics investors
InvestorRounds
Ontario Bioscience Innovation OrganizationGrant
Capital BioVenturesAccelerator, Seed
AyaWas GroupSeed
FACITSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2025

    Monthly visitors grew 491% MoM, from 32 to 189.

  • Dec 3, 2024

    Received funding from Capital BioVentures.

Virano Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Virano Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Virano Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range1
Year Founded2021
Last FundingOct 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?